Multicenter registry and test bed for extended outpatient hemodynamic monitoring: the hemodynamic frontiers in heart failure (HF
CardioMEMS
heart failure
hemodynamics
pulmonary artery pressure
pulmonary hypertension
remote monitoring
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
10
2023
accepted:
13
11
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
14
12
2023
Statut:
epublish
Résumé
Hemodynamic Frontiers in Heart Failure (HF HF HF This initial data set includes 254 patients implanted from the start of 2019 until May 2023. At time of device implant, the cohort average age is 73 years old, 59.8% are male, 72% have NYHA Class III HF, 40% have left ventricular ejection fraction (LVEF) < 40%, 35% have LVEF > 50%, mean BNP is 560 pg/ml, mean N-Terminal pro-BNP (NTproBNP) is 5,490 pg/ml, mean creatinine is 1.65 mg/dl. Average baseline hemodynamics at device implant are right atrial pressure (RAP) of 11 mmHg, pulmonary artery systolic pressure (PASP) of 47 mmHg, pulmonary artery diastolic pressure (PADP) 21 mmHg, mean pulmonary artery pressure (mPAP) of 20 mmHg, pulmonary capillary wedge pressure (PCWP) of 19 mmHg, cardiac output (CO) of 5.3 L/min, and cardiac index (CI) of 2.5 L/min/m A real-world registry of patients implanted with a PAP sensor enables long-term evaluation of hemodynamic and clinic outcomes in highly-phenotyped ambulatory HF patients, and creates a unique opportunity to validate and test novel diagnostic and therapeutic approaches to HF.
Sections du résumé
Background
UNASSIGNED
Hemodynamic Frontiers in Heart Failure (HF
Goals/aims
UNASSIGNED
HF
Methods
UNASSIGNED
HF
Results
UNASSIGNED
This initial data set includes 254 patients implanted from the start of 2019 until May 2023. At time of device implant, the cohort average age is 73 years old, 59.8% are male, 72% have NYHA Class III HF, 40% have left ventricular ejection fraction (LVEF) < 40%, 35% have LVEF > 50%, mean BNP is 560 pg/ml, mean N-Terminal pro-BNP (NTproBNP) is 5,490 pg/ml, mean creatinine is 1.65 mg/dl. Average baseline hemodynamics at device implant are right atrial pressure (RAP) of 11 mmHg, pulmonary artery systolic pressure (PASP) of 47 mmHg, pulmonary artery diastolic pressure (PADP) 21 mmHg, mean pulmonary artery pressure (mPAP) of 20 mmHg, pulmonary capillary wedge pressure (PCWP) of 19 mmHg, cardiac output (CO) of 5.3 L/min, and cardiac index (CI) of 2.5 L/min/m
Conclusion
UNASSIGNED
A real-world registry of patients implanted with a PAP sensor enables long-term evaluation of hemodynamic and clinic outcomes in highly-phenotyped ambulatory HF patients, and creates a unique opportunity to validate and test novel diagnostic and therapeutic approaches to HF.
Identifiants
pubmed: 38094114
doi: 10.3389/fcvm.2023.1321415
pmc: PMC10716259
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1321415Informations de copyright
© 2023 Heywood, Munshi, Jordan, Muse, Fudim, Sauer, McDermott, Shah, Bhimaraj, Khedraki, Robinson, McCann, Volz, Guha, Jonsson, Bhatt, Bennett, Benjamin, Guglin and Abraham.
Déclaration de conflit d'intérêts
TH received honoraria from Johnson and Johnson, United Therapeutics, Boehringer Ingelheim, Bayer, Lily as well as research grant support from Johnson and Johnson. JA is a consultant for Abiomed and Abbott, and is on the speaker's bureau for Abiomed, Abbott, Ancora. MF is a speaker for Abbott. AS disclosures include consulting for or receiving research funding from Abbott, Boston Scientific, Medtronic, Biotronik, Impulse Dynamics, Acorai, General Prognostics, Edwards Lifesciences, Story Health, Bayer, CSL Vifor. HS is a consultant for Endotronix and a speaker for Impulse Dynamics. AB is a consultant for Abbott. PM is a consultant for Abbott, AstraZeneca, Janssen, Daxor, and CVRx. OJ is a speaker for Abbott. KB is on the speaker's bureau for Abbott, Pfizer, and Novartis and is a consultant for Abbott and Vectorius. MB is a consultant for Abbott and Rhythm Management Group. TAB is a consultant for Abbott. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.